NF-κB-Activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer

Cell Reports

Volumn 11, Issue 1, 2015, Pages 98-110

  Blakely, Collin M ^a,b   Pazarentzos, Evangelos ^a,b   Olivas, Victor ^a,b   Asthana, Saurabh ^a,b   Yan, Jenny Jiacheng ^a,b   Tan, Irena ^a,b   Hrustanovic, Gorjan ^a,b   Chan, Elton ^a,b   Lin, Luping ^a,b   Neel, Dana S ^a,b   Newton, William ^a,d   Bobb, Kathryn L ^c   Fouts, Timothy R ^c   Meshulam, Jeffrey ^c   Gubens, Matthew A ^a,b   Jablons, David M ^a,b   Johnson, Jeffrey R ^a,d   Bandyopadhyay, Sourav ^b,e   Krogan, Nevan J ^a,d   Bivona, Trever G ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c J David Gladstone Institutes ^*  (United States)

^d GLADSTONE INSTITUTES   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PBS 1086; RECEPTOR INTERACTING PROTEIN 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; AGFG1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; CYCLOHEXANONE DERIVATIVE; EGFR PROTEIN, HUMAN; EPOXIDE; NUCLEOPORIN; PBS-1086; PROTEIN KINASE B; RNA BINDING PROTEIN;

ADAPTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER MODEL; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; FEMALE; GENETIC PARAMETERS; GENETIC TRANSCRIPTION; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; ONCOGENE; ONCOGENE INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR XENOGRAFT; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; APOPTOSIS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOHEXANONES; DRUG RESISTANCE, NEOPLASM; EPOXY COMPOUNDS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 2;

EID: 84927695240     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.03.012     Document Type: Article

References (57)

1. Alvarez S.E., Harikumar K.B., Hait N.C., Allegood J., Strub G.M., Kim E.Y., Maceyka M., Jiang H., Luo C., Kordula T., et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010, 465:1084-1088.
2. Anders S., Huber W. Differential expression analysis for sequence count data. Genome Biol. 2010, 11:R106.
3. Aoki Y., Kao P.N. Cyclosporin A-sensitive calcium signaling represses NFkappaB activation in human bronchial epithelial cells and enhances NFkappaB activation in Jurkat T-cells. Biochem. Biophys. Res. Commun. 1997, 234:424-431.
4. Berishaj M., Gao S.P., Ahmed S., Leslie K., Al-Ahmadie H., Gerald W.L., Bornmann W., Bromberg J.F. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res. 2007, 9:R32.
5. Bernstein B.E., Birney E., Dunham I., Green E.D., Gunter C., Snyder M. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. ENCODE Project Consortium.
6. Bivona T.G., Hieronymus H., Parker J., Chang K., Taron M., Rosell R., Moonsamy P., Dahlman K., Miller V.A., Costa C., et al. FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
7. Bromberg J.F., Wrzeszczynska M.H., Devgan G., Zhao Y., Pestell R.G., Albanese C., Darnell J.E. Stat3 as an oncogene. Cell 1999, 98:295-303.
8. Cox J., Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 2008, 26:1367-1372.
9. D'Angelo S.P., Pietanza M.C., Johnson M.L., Riely G.J., Miller V.A., Sima C.S., Zakowski M.F., Rusch V.W., Ladanyi M., Kris M.G. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J.Clin. Oncol. 2011, 29:2066-2070.
10. Ea C.K., Deng L., Xia Z.P., Pineda G., Chen Z.J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 2006, 22:245-257.
11. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
12. Ercan D., Xu C., Yanagita M., Monast C.S., Pratilas C.A., Montero J., Butaney M., Shimamura T., Sholl L., Ivanova E.V., et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov 2012, 2:934-947.
13. Fabre C., Mimura N., Bobb K., Kong S.Y., Gorgun G., Cirstea D., Hu Y., Minami J., Ohguchi H., Zhang J., et al. Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma. Clin. Cancer Res. 2012, 18:4669-4681.
14. Gao S.P., Mark K.G., Leslie K., Pao W., Motoi N., Gerald W.L., Travis W.D., Bornmann W., Veach D., Clarkson B., Bromberg J.F. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J.Clin. Invest. 2007, 117:3846-3856.
15. Goldberg S.B., Supko J.G., Neal J.W., Muzikansky A., Digumarthy S., Fidias P., Temel J.S., Heist R.S., Shaw A.T., McCarthy P.O., et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J.Thorac. Oncol. 2012, 7:1602-1608.
16. Gong Y., Somwar R., Politi K., Balak M., Chmielecki J., Jiang X., Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med. 2007, 4:e294.
17. Habib A.A., Chatterjee S., Park S.K., Ratan R.R., Lefebvre S., Vartanian T. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. J.Biol. Chem. 2001, 276:8865-8874.
18. Harhaj E.W., Sun S.C. Regulation of RelA subcellular localization by a putative nuclear export signal and p50. Mol. Cell. Biol. 1999, 19:7088-7095.
19. Hayden M.S., Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008, 132:344-362.
20. Hu J., Nakano H., Sakurai H., Colburn N.H. Insufficient p65 phosphorylation at S536 specifically contributes to the lack of NF-kappaB activation and transformation in resistant JB6 cells. Carcinogenesis 2004, 25:1991-2003.
21. Jiang Z., Clemens P.R. Cellular caspase-8-like inhibitory protein (cFLIP) prevents inhibition of muscle cell differentiation induced by cancer cells. FASEB J. 2006, 20:2570-2572.
22. Kim S.M., Kwon O.J., Hong Y.K., Kim J.H., Solca F., Ha S.J., Soo R.A., Christensen J.G., Lee J.H., Cho B.C. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol. Cancer Ther. 2012, 11:2254-2264.
23. Koeppen H., Yu W., Zha J., Pandita A., Penuel E., Rangell L., Raja R., Mohan S., Patel R., Desai R., et al. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin. Cancer Res. 2014, 20:4488-4498.
24. Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26:207-221.
25. Li B., Dewey C.N. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 2011, 12:323.
26. Li S., Wang L., Dorf M.E. PKC phosphorylation of TRAF2 mediates IKKalpha/beta recruitment and K63-linked polyubiquitination. Mol. Cell 2009, 33:30-42.
27. Lin L., Asthana S., Chan E., Bandyopadhyay S., Martins M.M., Olivas V., Yan J.J., Pham L., Wang M.M., Bollag G., et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. USA 2014, 111:E748-E757.
28. Lonardo F., Dragnev K.H., Freemantle S.J., Ma Y., Memoli N., Sekula D., Knauth E.A., Beebe J.S., Dmitrovsky E. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin. Cancer Res. 2002, 8:54-60.
29. Mahul-Mellier A.L., Pazarentzos E., Datler C., Iwasawa R., AbuAli G., Lin B., Grimm S. De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF. Cell Death Differ. 2012, 19:891-899.
30. Miller V.A., Hirsh V., Cadranel J., Chen Y.M., Park K., Kim S.W., Zhou C., Su W.C., Wang M., Sun Y., et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012, 13:528-538.
31. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N.Engl. J. Med. 2009, 361:947-957.
32. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., Puigserver P., Carlsson E., Ridderstråle M., Laurila E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 2003, 34:267-273.
33. Ng K.P., Hillmer A.M., Chuah C.T., Juan W.C., Ko T.K., Teo A.S., Ariyaratne P.N., Takahashi N., Sawada K., Fei Y., et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat. Med. 2012, 18:521-528.
34. O' Reilly L.A., Tai L., Lee L., Kruse E.A., Grabow S., Fairlie W.D., Haynes N.M., Tarlinton D.M., Zhang J.G., Belz G.T., et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
35. Ohashi K., Sequist L.V., Arcila M.E., Moran T., Chmielecki J., Lin Y.L., Pan Y., Wang L., de Stanchina E., Shien K., et al. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc. Natl. Acad. Sci. USA 2012, 109:E2127-E2133.
36. Ohashi K., Maruvka Y.E., Michor F., Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J.Clin. Oncol. 2013, 31:1070-1080.
37. Perkins N.D. The diverse and complex roles of NF-κB subunits in cancer. Nat. Rev. Cancer 2012, 12:121-132.
38. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 2006, 20:1496-1510.
39. Politi K., Fan P.D., Shen R., Zakowski M., Varmus H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis. Model. Mech. 2010, 3:111-119.
40. Puliyappadamba V.T., Chakraborty S., Chauncey S.S., Li L., Hatanpaa K.J., Mickey B., Noorani S., Shu H.K., Burma S., Boothman D.A., Habib A.A. Opposing effect of EGFRWT on EGFRvIII-mediated NF-κB activation with RIP1 as a cell death switch. Cell Rep. 2013, 4:764-775.
41. Quintás-Cardama A., Vaddi K., Liu P., Manshouri T., Li J., Scherle P.A., Caulder E., Wen X., Li Y., Waeltz P., et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010, 115:3109-3117.
42. Ramalingam S.S., Spigel D.R., Chen D., Steins M.B., Engelman J.A., Schneider C.P., Novello S., Eberhardt W.E., Crino L., Habben K., et al. Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer. J.Clin. Oncol. 2011, 29:4574-4580.
43. Raskatov J.A., Meier J.L., Puckett J.W., Yang F., Ramakrishnan P., Dervan P.B. Modulation of NF-κB-dependent gene transcription using programmable DNA minor groove binders. Proc. Natl. Acad. Sci. USA 2012, 109:1023-1028.
44. Renard P., Ernest I., Houbion A., Art M., Le Calvez H., Raes M., Remacle J. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 2001, 29:E21.
45. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., Bergethon K., Shaw A.T., Gettinger S., Cosper A.K., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 2011, 3:75ra26.
46. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010, 141:69-80.
47. Solca F., Dahl G., Zoephel A., Bader G., Sanderson M., Klein C., Kraemer O., Himmelsbach F., Haaksma E., Adolf G.R. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J.Pharmacol. Exp. Ther. 2012, 343:342-350.
48. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
49. Sun S.C., Ganchi P.A., Béraud C., Ballard D.W., Greene W.C. Autoregulation of the NF-kappa B transactivator RelA (p65) by multiple cytoplasmic inhibitors containing ankyrin motifs. Proc. Natl. Acad. Sci. USA 1994, 91:1346-1350.
50. Takezawa K., Pirazzoli V., Arcila M.E., Nebhan C.A., Song X., de Stanchina E., Ohashi K., Janjigian Y.Y., Spitzler P.J., Melnick M.A., et al. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Cancer Discov 2012, 2:922-933.
51. Tefferi A., Litzow M.R., Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N.Engl. J. Med. 2011, 365:1455-1457.
52. Timofeeva O.A., Tarasova N.I., Zhang X., Chasovskikh S., Cheema A.K., Wang H., Brown M.L., Dritschilo A. STAT3 suppresses transcription of proapoptotic genes in cancer cells with the involvement of its N-terminal domain. Proc. Natl. Acad. Sci. USA 2013, 110:1267-1272.
53. Turke A.B., Zejnullahu K., Wu Y.L., Song Y., Dias-Santagata D., Lifshits E., Toschi L., Rogers A., Mok T., Sequist L., et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010, 17:77-88.
54. Walter A.O., Sjin R.T., Haringsma H.J., Ohashi K., Sun J., Lee K., Dubrovskiy A., Labenski M., Zhu Z., Wang Z., et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013, 3:1404-1415.
55. Yu H.A., Arcila M.E., Rekhtman N., Sima C.S., Zakowski M.F., Pao W., Kris M.G., Miller V.A., Ladanyi M., Riely G.J. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin. Cancer Res. 2013, 19:2240-2247.
56. Zhang Z., Lee J.C., Lin L., Olivas V., Au V., LaFramboise T., Abdel-Rahman M., Wang X., Levine A.D., Rho J.K., et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat. Genet. 2012, 44:852-860.
57. Zhou C., Wu Y.L., Chen G., Feng J., Liu X.Q., Wang C., Zhang S., Wang J., Zhou S., Ren S., et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011, 12:735-742.